Myomo (MYO) Projected to Post Quarterly Earnings on Monday

Myomo (NYSEAMERICAN:MYO) will likely be announcing its Q4 2025 results before the market opens on Monday, March 9th. Analysts expect Myomo to post earnings of ($0.09) per share and revenue of $10.4030 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 13, 2026 at 5:00 PM ET.

Myomo Stock Down 1.2%

Shares of NYSEAMERICAN:MYO opened at $0.78 on Monday. The company has a market capitalization of $29.79 million, a PE ratio of -2.67 and a beta of 1.17. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.49 and a quick ratio of 2.10. The business has a fifty day moving average price of $0.89 and a two-hundred day moving average price of $0.94. Myomo has a 1 year low of $0.64 and a 1 year high of $6.30.

Institutional Trading of Myomo

Hedge funds and other institutional investors have recently modified their holdings of the business. LPL Financial LLC boosted its holdings in shares of Myomo by 132.9% in the fourth quarter. LPL Financial LLC now owns 177,000 shares of the company’s stock worth $161,000 after acquiring an additional 101,000 shares during the period. XTX Topco Ltd purchased a new stake in Myomo during the 4th quarter worth about $148,000. Acadian Asset Management LLC bought a new position in Myomo in the 1st quarter worth about $114,000. Lazard Asset Management LLC bought a new position in Myomo in the 2nd quarter worth about $98,000. Finally, New York State Common Retirement Fund purchased a new position in Myomo during the 2nd quarter valued at about $97,000. Institutional investors own 44.99% of the company’s stock.

Analysts Set New Price Targets

Separately, Ascendiant Capital Markets reduced their target price on shares of Myomo from $10.50 to $10.00 and set a “buy” rating for the company in a research report on Friday, November 21st. Four equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $7.67.

Myomo Company Profile

Myomo, Inc (NYSE American: MYO) is a medical robotics company specializing in developing and commercializing powered orthotic devices designed to restore mobility and function for individuals with upper-limb weakness. The company’s flagship product, the MyoPro®, is an FDA-cleared, wearable robotic orthosis that leverages proprietary sensors and actuators to detect and amplify users’ own muscle signals, enabling patients with conditions such as stroke, spinal cord injury, muscular dystrophy and other neuromuscular disorders to perform daily activities with greater independence.

Myomo markets the MyoPro through a network of licensed orthotic and prosthetic professionals, clinics and hospitals across North America.